Google Inc (GOOGL)’s Gift To Medical Researchers

It could well be termed as Google Inc (NASDAQ:GOOGL)’s gift to the researchers in the medical field. The company’s life sciences division has developed a health-tracking wristband purely for the benefit of the medical fraternity. The objective of the gadget is to provide minute-by-minute data on the patients’ progress during the clinical trials, as well as, the drug tests. The device would undoubtedly help the researchers and physicians to monitor a patient’s health.

Not A Consumer Device

Google Inc (NASDAQ:GOOGL)’s life sciences team head, Andy Conrad, indicated that the device will not be marketed as a consumer gadget, as reported by Bloomberg. The experimental device could gauge the patient’s heart rhythm, pulse, and skin temperature. Aside from this, the device will monitor environmental data such as noise levels and light exposure.

Conrad made it clear that the intention was to make the device useful for clinical trials. Alternatively, the company wants to promote the device through prescription to patients. The device will meet the long-pending aspiration of the researchers, doctors, and drug makers to track patients’ vital signs continuously outside the lab.

Big Challenge

Medidata MD for mobile health, Kara Dennis, termed it a big challenge to come out with a device that provides accurate data about the patients’ health. He also said that it is a tough challenge to come out with a gadget that is easy for the patients to use.

For the consumers, Google Inc (NASDAQ:GOOGL) has already been providing health-monitoring smartwatch features through its Android Wear software platform. That was through an alliance with LG Electronics. Apple Inc. (NASDAQ:AAPL) and others have also come out with the smartwatch wearable with health features. However, Conrad said that those devices are not providing meticulous data for the researchers. That makes the search engine giant’s device a unique one due to the role played by Google X.

Regulatory Clearance

The company’s official indicated that it will work closely with the academic researchers, as well as, the drug makers to test the device’s accuracy. For this, trials to test will commence during the summer season. Conrad said that the company would seek the approval from the regulator to use the device in the Americas and the Europe.

The search engine giant might also scout for a manufacturing partner. He pointed out that Novartis AG (ADR) (NYSE:NVS)’s Alcon unit has a license. Therefore, it will commercialize the contact lens.

Essential Tool

Google Inc (NASDAQ:GOOGL)’s executive said that the device would become an essential tool probably in two or three decades from now on. During that part of the time, physicians will prescribe the device to all the patients since prevention means all the time. That applies to even healthy people. The company’s lab was established to take big projects with the objective of long-term payoffs like the delivery drones, wind turbines, and driverless cars. The company also developed an experimental contact lens to read blood sugar levels of diabetic patients.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

Read previous post:
Facebook Inc (FB)’s 2 Trillion Video Views To Google Inc’s YouTube’s 3 Trillion By End of 2015

Facebook Inc (NASDAQ:FB) is taking on Google Inc (NASDAQ:GOOG)(NASDAQ:GOOGL)’s YouTube in a major way in the video sharing market. Currently,...